For more than a year, the biopharma industry has had to swiftly react to various tariff threats from the Trump administration. | The president has rolled out a 100% tariff rate on patented ...

As senior director of client services for The Trade Desk, Elizabeth Keenan oversees teams responsible for audience strategy, ...

On the heels of a comprehensive review, BioNTech has decided “to close its planned Singapore site by the end of February 2027 ...

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

The U.K. can officially declare itself free of tariffs on drug exports to the U.S. after its government signed off on the ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

Pfizer has emerged victorious in a legal brawl with Poland and Romania over contested COVID vaccine orders, with a Belgian ...

A year after revealing his “Liberation Day” trade policy initiatives, U.S. President Donald Trump is set to announce tariffs ...

Adragos Pharma, a German CDMO, has snapped up one of Europe’s largest sterile injectables production plants for an ...

The brief reign of Novo Nordisk’s Wegovy pill as the lone oral GLP-1 approved for obesity has ended as Eli Lilly’s ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...